Novartis to scale up data science under AI deal with Oxford

By Chris Lieu | Jan 18, 2019 | 12:08 AM GMT

Novartis AG (NYSE:NVS; SIX:NOVN) and the University of Oxford's Big Data Institute (BDI) will use artificial intelligence to analyze ultra large and multiple data sets from Novartis' drug development programs to identify

Read the full 322 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE